Connect your AI

Immunovant, Inc. IMVT Due to Roivant Sciences Ltd.

Other financials

Income statement

Net income-$147.9M-38.9%

EPS (diluted)-$0.73-15.9%

Balance sheet

Cash & equivalents$902.1M+26.4%

Total debt$72.0K-26.5%

Total equity$852.6M+20.5%

Total assets$957.0M+23.3%

Cash flow

Operating cash flow-$95.1M+14.1%

CapEx$8.0K-96.0%

Free cash flow-$95.1M+14.2%

Valuation

Market cap$7.26B+74.2%

Enterprise value$6.35B+89.7%

Returns & leverage

Return on equity-64.8%+2.5pp

Debt / equity0×0.0×

Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept imvt:AccruedRelatedPartyCostsCurrent.

The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s due to roivant sciences ltd..

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Immunovant, Inc.'s due to roivant sciences ltd.?: Immunovant, Inc. (IMVT) reported due to roivant sciences ltd. of $0 in Q4 2025.